FDA OKs trial of Terumo protocol for polymorphonuclear cells

01/8/2013 | InnovatioNews

The FDA has approved a trial to assess a collection protocol for polymorphonuclear cells using the Spectra Optia platform, according to Terumo BCT. Polymorphonuclear cells from donors could help patients whose immune systems are compromised due to illness or chemotherapy.

View Full Article in:

InnovatioNews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY